激素受体阳性/HER-2阴性乳腺癌新辅助内分泌治疗研究进展  

Advances in neoadjuvant endocrine therapy for hormone receptor-positive/HER-2-negative breast cancer

作　　者：毕钊 郑春辉[2] 王雪儿(综述) 王永胜(审校) Zhao Bi;Chunhui Zheng;Xue'er Wang;Yongsheng Wang(Breast Cancer Center,Shandong Cancer Hospital and Institute,Jinan 250000,China;Breast Cancer Center,Weifang People's Hospital,Weifang 262500,China)

机构地区：[1]山东省肿瘤防治研究院(山东省肿瘤医院)乳腺病中心,济南市250017 [2]潍坊市人民医院乳腺外科

出　　处：《中国肿瘤临床》2024年第18期963-967,共5页Chinese Journal of Clinical Oncology

摘　　要：激素受体阳性/HER-2阴性(hormone receptor positive/HER-2 negative,HR+/HER2-)乳腺癌化疗敏感性差,新辅助化疗并未带来明显获益。新辅助内分泌治疗(neoadjuvant endocrine therapy,NET)可以取得与新辅助化疗相似的客观缓解率和更低的毒性,成为一种有效的替代手段。同时,CDK4/6抑制剂改变了HR+/HER2-乳腺癌的治疗格局,对NET的优化选择提出了新的临床问题。在临床实践中应依据肿瘤生物学、疗效与肿瘤负荷,采用适应性研究设计,优化患者治疗策略,进行个体化、精准化治疗。本文就NET的应用价值、疗效评估及联合治疗等方面进行综述。Hormone receptor-positive/HER-2-negative(HR+/HER2-)breast cancer exhibits low sensitivity to neoadjuvant chemotherapy(NCT);with minimal benefits observed from NCT.Neoadjuvant endocrine therapy(NET)achieves a clinical response comparable to that of NCT,but with lower toxicity.In addition,CDK4/6 inhibitors have changed the treatment landscape of HR+/HER2-breast cancer,raising new clinical challenges in the selection of the most effective endocrine therapies.In clinical practice,adaptive research designs should be adopted based on tumor biology,therapeutic efficacy,and tumor burden.In addition,optimizing treatment strategies and performing precise treatment is important.In this review,we discuss the application value of NET,efficacy evaluating and predicting methods,and potential NET-based combination therapies to provide reference information regarding the treatment of HR+/HER2-breast cancer for clinicians.

关 键 词：乳腺癌 激素受体阳性/HER-2阴性亚型 新辅助内分泌治疗 CDK4/6抑制剂 

分 类 号：R737.9[医药卫生—肿瘤]